NEONC TECHNOLOGIES HOLDINGS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
23975 PARK SORRENTO, CALABASAS, CA, 91302
Mailing Address
23975 PARK SORRENTO, CALABASAS, CA, 91302
Phone
310 663 7831
Fiscal Year End
1231
EIN
921954864
Financial Overview
FY2025 FY
$83K
Revenue
-$11.90M
Net Income
$20.33M
Total Liabilities
-$5.50M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 12, 2026 | View on SEC |
| S-1 IPO registration statement | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- NEO100 clinical trial results expected by end of 2024, one year ahead of schedule.
- NEO100 demonstrated a 21% positive response rate, significantly outperforming the 8% historical benchmark.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.